Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1093/jnci/85.5.365 | The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology |
| https://doi.org/10.1038/nature12477 | Signatures of mutational processes in human cancer |
| https://doi.org/10.1056/nejmoa052306 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer |
| https://doi.org/10.1056/nejmoa033025 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer |
| https://doi.org/10.1016/s0140-6736(13)62422-8 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis |
| https://doi.org/10.1093/annonc/mdt303 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 |
| https://doi.org/10.1038/s41586-020-1943-3 | The repertoire of mutational signatures in human cancer |
| Features, Evaluation and Treatment Coronavirus (COVID-19) | |
| https://doi.org/10.1038/s41586-020-1969-6 | Pan-cancer analysis of whole genomes |
| https://doi.org/10.1093/annonc/mdu450 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 |
| https://doi.org/10.1056/nejmoa1109653 | Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer |
| https://doi.org/10.1056/nejmoa2203690 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
| https://doi.org/10.1056/nejm199512073332305 | Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma |
| https://doi.org/10.1038/nature17676 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences |
| https://doi.org/10.1093/annonc/mdw544 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) |
| https://doi.org/10.1056/nejmoa1602253 | 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer |
| https://doi.org/10.1093/annonc/mdv221 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 |
| https://doi.org/10.1056/nejmoa032312 | A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer |
| https://doi.org/10.1056/nejmoa071028 | Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer |
| https://doi.org/10.1200/jco.2011.41.0902 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 |
| https://doi.org/10.1056/nejmoa2105215 | Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer |
| https://doi.org/10.1093/annonc/mdy096 | Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| https://doi.org/10.1016/s0140-6736(07)60028-2 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial |
| https://doi.org/10.1056/nejmoa2028485 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer |
| https://doi.org/10.1056/nejmra0801289 | Gene-Expression Signatures in Breast Cancer |
| https://doi.org/10.1056/nejmoa1703643 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer |
| https://doi.org/10.1016/j.annonc.2021.09.019 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer |
| https://doi.org/10.1016/s0140-6736(11)61847-3 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial |
| https://doi.org/10.1056/nejm199202203260805 | Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer |
| https://doi.org/10.1093/annonc/mdu112 | Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial |
| https://doi.org/10.1093/annonc/mdx308 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 |
| https://doi.org/10.1056/nejmoa1611750 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma |
| https://doi.org/10.1161/circulationaha.120.048360 | Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic |
| https://doi.org/10.1038/s41571-020-00457-x | Liquid biopsy enters the clinic — implementation issues and future challenges |
| https://doi.org/10.1016/s0140-6736(05)67101-2 | Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) |
| https://doi.org/10.1038/nm.4292 | HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures |
| https://doi.org/10.1038/s41586-019-1907-7 | The evolutionary history of 2,658 cancers |
| https://doi.org/10.1016/s0140-6736(11)60070-6 | Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study |
| https://doi.org/10.1111/his.14091 | The 2019 World Health Organization classification of tumours of the breast |
| https://doi.org/10.1172/jci67428 | CD4+ follicular helper T cell infiltration predicts breast cancer survival |
| https://doi.org/10.1016/s0140-6736(16)32616-2 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial |
| https://doi.org/10.1016/s0140-6736(98)03085-2 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer |
| https://doi.org/10.1158/1078-0432.ccr-06-2765 | Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series |
| https://doi.org/10.1038/s41586-019-1913-9 | Patterns of somatic structural variation in human cancer genomes |
| https://doi.org/10.1016/j.annonc.2019.10.023 | Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations |
| https://doi.org/10.1016/s0140-6736(15)01159-9 | Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial |
| https://doi.org/10.1038/sj.bjc.6603756 | Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients |
| https://doi.org/10.1016/j.annonc.2021.07.006 | Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ |
| https://doi.org/10.1016/s0140-6736(19)31240-1 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study |
| https://doi.org/10.1038/nbt.1665 | The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models |
| https://doi.org/10.1038/nrclinonc.2015.215 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic |
| https://doi.org/10.1186/bcr2124 | Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures |
| https://doi.org/10.1056/nejmoa011807 | Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density |
| https://doi.org/10.1200/jco.18.01010 | Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers |
| https://doi.org/10.1200/jco.2005.06.124 | Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors |
| https://doi.org/10.1016/s0140-6736(12)61253-7 | Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) |
| https://doi.org/10.1056/nejm199501263320403 | Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia |
| https://doi.org/10.1093/annonc/mds293 | Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines |
| https://doi.org/10.1158/1078-0432.ccr-07-4756 | Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes |
| https://doi.org/10.1038/nm.3886 | Subclonal diversification of primary breast cancer revealed by multiregion sequencing |
| https://doi.org/10.1016/s1470-2045(14)70069-5 | Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data |
| https://doi.org/10.1016/s0959-8049(00)00186-6 | A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients |
| https://doi.org/10.1093/annonc/mdv249 | A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) |
| https://doi.org/10.1097/pap.0000000000000161 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors |
| https://doi.org/10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s | Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1 |
| https://doi.org/10.1093/annonc/mdt199 | Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| https://doi.org/10.1093/annonc/mdy517 | Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study |
| https://doi.org/10.1186/s12916-015-0545-7 | Cancer and fertility preservation: international recommendations from an expert meeting |
| https://doi.org/10.1023/b:brea.0000014042.54925.cc | Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update |
| https://doi.org/10.1183/09031936.00214014 | Towards tuberculosis elimination: an action framework for low-incidence countries |
| https://doi.org/10.1038/sj.onc.1208561 | Identification of molecular apocrine breast tumours by microarray analysis |
| https://doi.org/10.1093/annonc/mdy095 | Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| https://doi.org/10.1093/annonc/mdw325 | Management of febrile neutropaenia: ESMO Clinical Practice Guidelines |
| https://doi.org/10.1016/s1470-2045(13)70599-0 | Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study |
| https://doi.org/10.1200/jco.1992.10.1.52 | High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. |
| https://doi.org/10.1097/pap.0000000000000162 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research |
| https://doi.org/10.1111/j.1600-0749.2006.00334.x | Hypopigmenting agents: an updated review on biological, chemical and clinical aspects |
| https://doi.org/10.1016/j.ccell.2017.07.005 | Genomic Evolution of Breast Cancer Metastasis and Relapse |
| https://doi.org/10.1093/annonc/mdz235 | Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 |
| https://doi.org/10.1200/jco.22.00338 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial |
| https://doi.org/10.1038/s41523-018-0097-z | MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer |
| https://doi.org/10.1097/00000658-198811000-00011 | Preoperative Radiotherapy as Adjuvant Treatment in Rectal Cancer |
| https://doi.org/10.1056/nejmoa1903455 | Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma |
| https://doi.org/10.1158/1078-0432.ccr-07-1755 | hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer |
| https://doi.org/10.1158/1078-0432.ccr-08-1080 | Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer |
| https://doi.org/10.1038/s41586-020-1965-x | Analyses of non-coding somatic drivers in 2,658 cancer whole genomes |
| https://doi.org/10.1200/jco.21.01015 | First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study |
| https://doi.org/10.1016/s0140-6736(08)61033-8 | Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial |
| https://doi.org/10.1093/annonc/mdx310 | ESMO-Magnitude of Clinical Benefit Scale version 1.1 |
| https://doi.org/10.1007/bf00434949 | International quality of life assessment (IQOLA) project |
| https://doi.org/10.1093/annonc/mdy310 | Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| https://doi.org/10.1038/nm.1908 | A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer |
| https://doi.org/10.1182/blood-2008-12-196543 | Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study |
| https://doi.org/10.1016/s1470-2045(11)70033-x | Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial |
| https://doi.org/10.1038/sj.bjc.6602258 | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
| https://doi.org/10.1001/jamaoncol.2015.0830 | Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab |
| https://doi.org/10.1093/annonc/mdg019 | A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy |
| https://doi.org/10.1016/j.annonc.2021.07.016 | EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours |
| https://doi.org/10.1038/ncomms10582 | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy |
| https://doi.org/10.1093/annonc/mdu456 | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 |